AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain
This article was originally published in The Pink Sheet Daily
Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.
You may also be interested in...
Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.
As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.